CHANCHAL PANT: Open Payments
NPI 1386319291 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$397 in 17 payments from 11 companies in 2025. Trend: 2023 $578 · 2024 $375 · 2025 $397
Food & beverage: $397
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 4 | $95 |
| Amgen Inc. | 3 | $64 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Calliditas Therapeutics US Inc. | 1 | $31 |
| SCPHARMACEUTICALS INC. | 1 | $28 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Ardelyx, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
Products named: VELPHORO, TAVNEOS, PURIFIED CORTROPHIN GEL, TARPEYO, FUROSCIX, LUPKYNIS, IBSRELA, JYNARQUE.
Industry payments across DE — which companies pay providers there.
